These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8906105)

  • 1. A novel phosphodiesterase inhibitor, T-440: possible management of eosinophilic inflammation by down-regulation of interleukin-5 production.
    Kaminuma O; Mori A; Suko M; Nishizaki Y; Kikkawa H; Ikezawa K; Okudaira H
    Int Arch Allergy Immunol; 1996; 111 Suppl 1():16-8. PubMed ID: 8906105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-5 production by peripheral blood mononuclear cells of asthmatic patients is suppressed by T-440: relation to phosphodiesterase inhibition.
    Kaminuma O; Mori A; Suko M; Kikkawa H; Ikezawa K; Okudaira H
    J Pharmacol Exp Ther; 1996 Oct; 279(1):240-6. PubMed ID: 8858999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A selective type 4 phosphodiesterase inhibitor, T-440, modulates intracellular cyclic AMP level and interleukin-2 production of Jurkat cells.
    Kaminuma O; Mori A; Wada K; Kikkawa H; Ikezawa K; Suko M; Okudaira H
    Immunopharmacology; 1998 Jan; 38(3):247-52. PubMed ID: 9506824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor.
    Foissier L; Lonchampt M; Cogé F; Canet E
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1484-90. PubMed ID: 8819536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced production and gene expression of interleukin-5 in patients with bronchial asthma: possible management of atopic diseases by down-regulation of interleukin-5 gene transcription.
    Okudaira H; Mori A; Suko M; Etoh T; Nakagawa H; Ito K
    Int Arch Allergy Immunol; 1995; 107(1-3):255-8. PubMed ID: 7542077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated cAMP-phosphodiesterase in atopic disease: cause or effect?
    Townley RG
    J Lab Clin Med; 1993 Jan; 121(1):15-7. PubMed ID: 8381147
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
    Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation.
    Gantner F; Götz C; Gekeler V; Schudt C; Wendel A; Hatzelmann A
    Br J Pharmacol; 1998 Mar; 123(6):1031-8. PubMed ID: 9559883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
    J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects.
    Landells LJ; Szilagy CM; Jones NA; Banner KH; Allen JM; Doherty A; O'Connor BJ; Spina D; Page CP
    Br J Pharmacol; 2001 Jul; 133(5):722-9. PubMed ID: 11429397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expression in peripheral blood mononuclear cells.
    Essayan DM; Huang SK; Kagey-Sobotka A; Lichtenstein LM
    Am J Respir Cell Mol Biol; 1995 Dec; 13(6):692-702. PubMed ID: 7576707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis.
    Banner KH; Roberts NM; Page CP
    Br J Pharmacol; 1995 Dec; 116(8):3169-74. PubMed ID: 8719792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asthma and airway inflammation: potential anti-inflammatory activities of phosphodiesterase inhibitors.
    Lagente V; Hichami A; Boichot E; Martins MA; Silva PM
    Allerg Immunol (Paris); 1995 Feb; 27(2):34-9. PubMed ID: 7710653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
    Barnette MS; Manning CD; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
    J Pharmacol Exp Ther; 1995 May; 273(2):674-9. PubMed ID: 7752069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-5 production by bronchoalveolar lavage and peripheral blood mononuclear cells in asthma and atopy.
    Tang C; Rolland JM; Ward C; Quan B; Walters EH
    Eur Respir J; 1997 Mar; 10(3):624-32. PubMed ID: 9072996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary antiallergic and antiinflammatory effects of a novel, orally-active phosphodiesterase IV inhibitor (WAY-127093B) in guinea pigs and rats.
    Howell RE; Woeppel SL; Howell DE; Rubin EB; Jenkins LP; Golankiewicz JM; Lombardo LJ; Heaslip RJ
    Inflamm Res; 1995 Aug; 44 Suppl 2():S172-3. PubMed ID: 8548383
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.
    Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R
    Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol.
    Dent G; Giembycz MA; Evans PM; Rabe KF; Barnes PJ
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1167-74. PubMed ID: 7996422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.